NO146499C - Fremgangsmaate for fremstilling av krystallinsk alfa-form av prazosin. - Google Patents

Fremgangsmaate for fremstilling av krystallinsk alfa-form av prazosin.

Info

Publication number
NO146499C
NO146499C NO770674A NO770674A NO146499C NO 146499 C NO146499 C NO 146499C NO 770674 A NO770674 A NO 770674A NO 770674 A NO770674 A NO 770674A NO 146499 C NO146499 C NO 146499C
Authority
NO
Norway
Prior art keywords
crystallinic
prazosin
procedure
preparation
alfa
Prior art date
Application number
NO770674A
Other languages
English (en)
Other versions
NO146499B (no
NO770674L (no
Inventor
Ernest John Bianco
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO770674L publication Critical patent/NO770674L/no
Publication of NO146499B publication Critical patent/NO146499B/no
Publication of NO146499C publication Critical patent/NO146499C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
NO770674A 1976-03-01 1977-02-28 Fremgangsmaate for fremstilling av krystallinsk alfa-form av prazosin. NO146499C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/662,937 US4092315A (en) 1976-03-01 1976-03-01 Novel crystalline forms of prazosin hydrochloride

Publications (3)

Publication Number Publication Date
NO770674L NO770674L (no) 1977-09-02
NO146499B NO146499B (no) 1982-07-05
NO146499C true NO146499C (no) 1982-10-13

Family

ID=24659839

Family Applications (1)

Application Number Title Priority Date Filing Date
NO770674A NO146499C (no) 1976-03-01 1977-02-28 Fremgangsmaate for fremstilling av krystallinsk alfa-form av prazosin.

Country Status (32)

Country Link
US (1) US4092315A (no)
JP (1) JPS604188B2 (no)
AR (1) AR210937A1 (no)
AU (1) AU506937B2 (no)
BE (1) BE851878A (no)
BG (1) BG29724A3 (no)
CA (1) CA1068269A (no)
CH (1) CH618436A5 (no)
CS (1) CS191332B2 (no)
DD (1) DD129652A5 (no)
DE (1) DE2708192C3 (no)
DK (1) DK145858C (no)
ES (1) ES8707447A1 (no)
FI (1) FI62082C (no)
FR (1) FR2372828A1 (no)
GB (1) GB1538713A (no)
HK (1) HK30881A (no)
HU (1) HU173641B (no)
IE (1) IE44522B1 (no)
IL (1) IL51481A (no)
LU (1) LU76868A1 (no)
MY (1) MY8100271A (no)
NL (1) NL169591C (no)
NO (1) NO146499C (no)
NZ (1) NZ183450A (no)
PL (1) PL105559B1 (no)
PT (1) PT66227B (no)
RO (1) RO73095A (no)
SE (1) SE423234B (no)
SU (1) SU644387A3 (no)
YU (1) YU41294B (no)
ZA (1) ZA77918B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
MX5483E (es) * 1977-08-04 1983-08-23 Abbott Lab Procedimiento para la preparacion del dihidrato clorhidrato de 1-(4-amino-6,7-dimetoxi-2-quinazolinil)-4-(2-tetrahidrofuroil)piperazina
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
US4440769A (en) * 1983-02-11 1984-04-03 Abbott Laboratories 2-(4-Phenylalkanoylpiperazin-1-yl) quinazoline compounds, pharmaceutical compositions and method of producing α1 antagonistic activity
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US5322943A (en) * 1985-09-12 1994-06-21 The Upjohn Company Piperazine compounds which are substituted
US4601897A (en) * 1985-11-06 1986-07-22 Pfizer Inc. Prazosin-pirbuterol combination for bronchodilation
EP0237608B1 (de) * 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
US5110927A (en) * 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
DK0849266T3 (da) * 1996-12-20 2007-06-04 Heumann Pcs Gmbh Hidtil ukendt polymorf form af doxazosin-mesylat (form III)
US9976252B2 (en) 2014-07-21 2018-05-22 Keir Manufacturing, Inc. Aerodynamic flyer bow

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines

Also Published As

Publication number Publication date
CA1068269A (en) 1979-12-18
JPS604188B2 (ja) 1985-02-01
LU76868A1 (no) 1977-09-21
IE44522B1 (en) 1981-12-30
PT66227B (en) 1978-07-14
AU2244377A (en) 1978-11-23
CH618436A5 (no) 1980-07-31
IE44522L (en) 1977-09-01
BE851878A (fr) 1977-08-29
GB1538713A (en) 1979-01-24
PT66227A (en) 1977-03-01
HK30881A (en) 1981-07-10
JPS52105206A (en) 1977-09-03
NL169591C (nl) 1982-08-02
US4092315A (en) 1978-05-30
FI62082B (fi) 1982-07-30
HU173641B (en) 1979-07-28
BG29724A3 (en) 1981-01-15
AU506937B2 (en) 1980-01-31
NZ183450A (en) 1979-03-16
NL7702123A (nl) 1977-09-05
DK145858C (da) 1983-09-12
DK86877A (da) 1977-09-02
FI770634A (no) 1977-09-02
PL196354A1 (pl) 1978-02-27
ES545368A0 (es) 1978-06-01
DE2708192C3 (de) 1980-05-08
NO146499B (no) 1982-07-05
DE2708192B2 (de) 1979-08-02
MY8100271A (en) 1981-12-31
YU41294B (en) 1987-02-28
FR2372828A1 (fr) 1978-06-30
SU644387A3 (ru) 1979-01-25
ZA77918B (en) 1977-12-28
IL51481A (en) 1980-09-16
RO73095A (ro) 1981-06-26
DD129652A5 (de) 1978-02-01
FR2372828B1 (no) 1980-02-01
ES8707447A1 (es) 1987-08-16
IL51481A0 (en) 1977-04-29
FI62082C (fi) 1982-11-10
SE423234B (sv) 1982-04-26
NL169591B (nl) 1982-03-01
DE2708192A1 (de) 1977-09-08
AR210937A1 (es) 1977-09-30
PL105559B1 (pl) 1979-10-31
YU49977A (en) 1983-12-31
DK145858B (da) 1983-03-21
CS191332B2 (en) 1979-06-29
SE7701624L (sv) 1977-09-02
NO770674L (no) 1977-09-02

Similar Documents

Publication Publication Date Title
SE7505040L (sv) Forfarande for framstellning av n-fosfonometylglycin.
SE441827B (sv) Forfarande for framstellning av fenoxiaminopropanoler
NO770286L (no) Fremgangsm}te til fremstilling av dinatriumkromglycat.
NO774404L (no) Fremgangsmaate for fremstilling av dimetyleter
NO803591L (no) Fremgangsmaate for fremstilling av fiskemel.
NO146499C (no) Fremgangsmaate for fremstilling av krystallinsk alfa-form av prazosin.
NO770366L (no) Fremgangsm}te for fremstilling av meta-aryloksy-benzaldehyder.
SE435387B (sv) Forfarande for framstellning av antracyklinglykosider
NO143992C (no) Fremgangsmaate for fremstilling av heksanitrostilben
NO151365C (no) Fremgangsmaate for fremstilling av 4-halogen-dihydropyran-derivater.
SE7704139L (sv) Forfarande for framstellning av azofergemnen
SE436026B (sv) Forfarande for framstellning av 13,14-dehydroprostaglandiner
NO152645C (no) Fremgangsmaate for fremstilling av klordioksyd.
RO75589A (ro) Procedeu pentru prepararea 2,6-metan-2h-1-benzoxocinei
NO774067L (no) Fremgangsmaate for fremstilling av cellulosemasse
SE7707471L (sv) Forfarande for framstellning av 5-m-tolyloxiuracil
SE7503628L (sv) Forfarande for framstellning av silver-ii-oxid for galvaniska element.
SE7712218L (sv) Forfarande for framstellning av 4a-aryloktahydro-1h-2-pyrindiner
SE7707811L (sv) Forfarande for framstellning av p.isobutyl-hydratropat av guajakol
SE7601605L (sv) Forfarande for framstellning av 1 alfa,25-dihydroxi-cholkalciferol
NO770673L (no) Fremgangsm}te for fremstilling av benzylestere.
SE7709142L (sv) Forfarande for framstellning av 1-aryloxi-3-amino-propan-2-oler
SE7702071L (sv) Forfarande for framstellning av sulfoacetaler
SE7507482L (sv) Forfarande for framstellning av substituerade l-sulfonylbensimidazoler.
NO144067C (no) Fremgangsmaate for fremstilling av di-n-propylacetonitril.